Broadcast Date: Thursday, February 06, 2020
from 3:00 pm to 4:00 pm (ET)


Since the beginning of 2019, the number of biosimilar litigation – particularly those concerning the Biologics Price Competition and Innovation Act (BPCIA) “patent dance” – has drastically increased. One of the notable BCPIA cases that are being closely watched, is Amgen’s legal battle with Novartis’ Sandoz arm over the Enbrel patent, in which the former intends to hold commercial exclusivity for Enbrel until 2029. The legal precedents established in this dispute are expected to impact the biosimilar market as well as the pending and future biosimilar patent lawsuits.

With the changing biosimilar landscape and stiffer competition in the backdrop, counsel to drug companies should keep an eye out for these lawsuits and other legal developments to devise effective patent management and litigation strategies.

Listen to patent experts, Sean Sheridan (Charles River Associates) and Eberle Schultz (O’Melveny & Myers LLP) as they provide the audience with an in-depth analysis of the recent biosimilar litigation trends relating to the BPCIA patent dance. Speakers will also offer the best patent management and litigation practices in light of the recent developments.

This LIVE Webcast will discuss the following key provisions:

  • The BPCIA Patent Dance – Statistics and Recent Trends
  • Notable Cases and Court Decisions
  • Best Patent Management Practices
  • Effective Litigation Strategies
  • Outlook


Course Level:



Advance Preparation:

Print and review course materials


Method of Presentation:

On-demand Webcast (CLE)



General knowledge of biosimilar patent laws


Course Code:



NY Category of CLE Credit:

Areas of Professional Practice


Total Credit:

1.0 CLE

Speaker Panel:

Sean Sheridan, Ph.D., Principal
Charles River Associates

Dr. Sheridan is a principal in the Intellectual Property Practice at Charles River Associates. He has addressed a broad range of financial and economic issues in the context of litigation, including lost profits, unjust enrichment, reasonable royalty, commercial success, irreparable harm, and the economic prong of the domestic industry requirement in Section 337 ITC matters. The engagements he has worked on span a wide range of industries, and include pharmaceuticals, biologics, diagnostics and medical devices. Previously, Dr. Sheridan was as an assistant director at the technology transfer office at the University of Chicago, where he worked for five years, focusing primarily on the commercialization of early stage technologies.  Dr. Sheridan was named to the IAM Patent 1000: The World’s Leading Patent Professionals (economic experts) in 2019.

Eberle Schultz, Counsel
O'Melveny & Myers LLP

Eberle Schultz is a Counsel at O’Melveny & Myers where she practices complex patent litigation within the biotechnology, pharmaceutical, and chemical industries.  Eberle counsels life sciences clients in all aspects of patent litigation to help businesses achieve their strategic goals.

Eberle represents innovator pharmaceutical companies in patent ligation under the Hatch-Waxman Act and is experienced in innovator declaratory judgement actions, inter partes review proceedings before the Patent Trial and Appeal Board, Federal Circuit appeals, licensing disputes, and patent validity opinions.  She has litigated a variety of technologies, including multiple anti-cancer therapies and biologics.



Sean Sheridan, Ph.D.Principal

Charles River Associates

  • Overview of the Economics of the Biosimilar Market in the U.S., including:
    • Similarities and Differences with the Generic Pharmaceutical Market
    • Market Penetration and Pricing of Biosimilars
  • Discussion of How the Economics of Biosimilars May Impact Litigation-related Issues, including:
  • Evaluating Potential Damages Exposure and Whether to Launch at-risk
  • Evaluating Irreparable Harm When Seeking a Preliminary Injunction


Eberle SchultzCounsel

O'Melveny & Myers LLP

  • Litigation Landscape in 2020
  • Highlights of Litigation in 2019
  • Cases Won and Lost
  • Cases to Look to in 2020

Date & Time:

Thursday, February 06, 2020

3:00 pm to 4:00 pm (ET)

Who Should Attend:

  • Biotech and Pharmaceutical Companies
  • Patent Lawyers and Consultants
  • Patent Litigators
  • In-house Counsel
  • Top Level Management
Preventing Ransomware Attacks: A Practical Guide to Enhancing IT Security and Resiliency,
Speaker Preferred Package (Online Payment)
Asbestos Litigation: Demystifying Trends, Developments, and Defense Strategies,
New York Online CLE Bundle
Pennsylvania Online CLE Bundle
California Online CLE Bundle
Supercharging Privilege Review With AI, Analytics, and Automation,
The Hows and Whys of Child Abuse Reporting: A Comprehensive Ethical Guide for Lawyers,
Understanding R&D Tax Credits and Amortization: Navigating Changes and Maximizing Benefits,
Maximizing Your Innovation ROI: R&D Tax Credits in 2024 and Beyond,
Winning Patent Litigation: Essential Strategies and Tactics,
Cartel Investigations: A Blueprint for Defense,
Demystifying Economic Sanctions: Strategies for Success in a Global Economy,
Antitrust 'No-Poach' Agreement Enforcement: Key Focus Areas in 2024,
Practical Trademark Perspectives from U.S. and Canadian Counsel,
Effectively Manage KYC Compliance: Keep Up with the Times by Getting Back to Basics,
OFAC Regulations and the Economic Sanctions Compliance Programs: Best Practices,
'Zombie' LIBOR for USD Contracts: Navigating the Critical Issues, ,
Calculating Lost Profits in Construction Claims: A Practical Guide,
False Claims Act and COVID-19 Implications: Key Considerations and Best Practices, ,


Sean Sheridan, Ph.D.Principal
Charles River Associates
Eberle SchultzCounsel
O'Melveny & Myers LLP



View Details


View Details


View Details

Join Over 160,000 Professionals Empowering Their Careers

Learn anywhere from over 3000+ live and recorded CLE, CPE & Technology Webcasts.